Therapy-related myeloid neoplasms (t-MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t-MN patients, recruited between 1999 and 2013 by the Italian Network on Secondary Leukemias (104 retrospectively and 173 prospectively registered). Median age at t-MN diagnosis was 64 years (range, 21-87). Most frequent primary malignancies (PMs) were lymphoproliferative diseases and breast cancer. One hundred and thirty-three patients had received chemotherapy (CHT), 43 patients radiotherapy (RT), and 101 patients combined CHT/RT for PM. Median time between cytotoxic treatment and t-MN was 5.7 years, with t-MN following RT alone associated with significantly longer latency, compared to CHT or combined CHT/RT (mean, 11.2 vs. 7.1 years, P=0.0005). The addition of topoisomerase-II inhibitors to alkylating agents was associated with shorter latency compared to alkylating agents alone (median, 6 vs. 8.4 years, P=0.02). Median survival was 14.6 months from t-MN diagnosis, and was significantly longer in patients treated with allogeneic stem cell transplantation. Significant factors for survival at the multivariable analysis included age, adverse karyotype, and degree of anemia. Our data underline the prognostic importance of karyotype and age in t-MN, similar to de novo acute myeloid leukemia. Treatment approaches should not preclude the use of conventional treatments for younger t-MN patients, including allogeneic stem cell transplantation as potentially curative approach.

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias / Fianchi, L.; Pagano, L.; Piciocchi, A.; Candoni, A.; Gaidano, G.; Breccia, M.; Criscuolo, M.; Specchia, G.; Maria Pogliani, E.; Maurillo, L.; Aloe-Spiriti, M. A.; Mecucci, C.; Niscola, P.; Rossetti, E.; Mansueto, G.; Rondoni, M.; Fozza, C.; Invernizzi, R.; Spadea, A.; Fenu, S.; Buda, G.; Gobbi, M.; Fabiani, E.; Sica, S.; Hohaus, S.; Leone, G.; Voso, M. T.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 90:5(2015), pp. E80-E85. [10.1002/ajh.23966]

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

Candoni A.;
2015

Abstract

Therapy-related myeloid neoplasms (t-MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t-MN patients, recruited between 1999 and 2013 by the Italian Network on Secondary Leukemias (104 retrospectively and 173 prospectively registered). Median age at t-MN diagnosis was 64 years (range, 21-87). Most frequent primary malignancies (PMs) were lymphoproliferative diseases and breast cancer. One hundred and thirty-three patients had received chemotherapy (CHT), 43 patients radiotherapy (RT), and 101 patients combined CHT/RT for PM. Median time between cytotoxic treatment and t-MN was 5.7 years, with t-MN following RT alone associated with significantly longer latency, compared to CHT or combined CHT/RT (mean, 11.2 vs. 7.1 years, P=0.0005). The addition of topoisomerase-II inhibitors to alkylating agents was associated with shorter latency compared to alkylating agents alone (median, 6 vs. 8.4 years, P=0.02). Median survival was 14.6 months from t-MN diagnosis, and was significantly longer in patients treated with allogeneic stem cell transplantation. Significant factors for survival at the multivariable analysis included age, adverse karyotype, and degree of anemia. Our data underline the prognostic importance of karyotype and age in t-MN, similar to de novo acute myeloid leukemia. Treatment approaches should not preclude the use of conventional treatments for younger t-MN patients, including allogeneic stem cell transplantation as potentially curative approach.
2015
90
5
E80
E85
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias / Fianchi, L.; Pagano, L.; Piciocchi, A.; Candoni, A.; Gaidano, G.; Breccia, M.; Criscuolo, M.; Specchia, G.; Maria Pogliani, E.; Maurillo, L.; Aloe-Spiriti, M. A.; Mecucci, C.; Niscola, P.; Rossetti, E.; Mansueto, G.; Rondoni, M.; Fozza, C.; Invernizzi, R.; Spadea, A.; Fenu, S.; Buda, G.; Gobbi, M.; Fabiani, E.; Sica, S.; Hohaus, S.; Leone, G.; Voso, M. T.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 90:5(2015), pp. E80-E85. [10.1002/ajh.23966]
Fianchi, L.; Pagano, L.; Piciocchi, A.; Candoni, A.; Gaidano, G.; Breccia, M.; Criscuolo, M.; Specchia, G.; Maria Pogliani, E.; Maurillo, L.; Aloe-Spiriti, M. A.; Mecucci, C.; Niscola, P.; Rossetti, E.; Mansueto, G.; Rondoni, M.; Fozza, C.; Invernizzi, R.; Spadea, A.; Fenu, S.; Buda, G.; Gobbi, M.; Fabiani, E.; Sica, S.; Hohaus, S.; Leone, G.; Voso, M. T.
File in questo prodotto:
File Dimensione Formato  
ajh.23966.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 1.11 MB
Formato Adobe PDF
1.11 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294119
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 85
  • ???jsp.display-item.citation.isi??? 82
social impact